Status:
COMPLETED
Retapamulin for Reducing MRSA Nasal Carriage
Lead Sponsor:
University of California, Irvine
Collaborating Sponsors:
Agency for Healthcare Research and Quality (AHRQ)
Conditions:
Methicillin-Resistant Staphylococcus Aureus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators will conduct a randomized placebo-controlled double-blinded study of nasal decolonization with retapamulin vs. placebo for the eradication of MRSA nasal carriage among adult carriers...
Detailed Description
This study will evaluate the utility of retapamulin, a topical ointment FDA approved for skin infection, as a novel agent for MRSA decolonization and prevention of healthcare-associated MRSA infection...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Have a type of MRSA that is resistant to mupirocin (a drug used to treat MRSA)
Exclusion
- Allergic to retapamulin
- Unable to use retapamulin via your nose (i.e. nose surgery, etc.)
- Are pregnant and/or breastfeeding
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01461668
Start Date
July 1 2012
End Date
December 1 2017
Last Update
April 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irivne
Irvine, California, United States, 92617